|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Scagliotti GV, Parikh P, von Pawel J, et
al: Phase III study comparing cisplatin plus gemcitabine with
cisplatin plus pemetrexed in chemotherapy-naive patients with
advanced-stage non-small-cell lung cancer. J Clin Oncol.
26:3543–3551. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Schiller JH, Harrington D, Belani CP, et
al: Comparison of four chemotherapy regimens for advanced
non-small-cell lung cancer. N Engl J Med. 346:92–98. 2002.
View Article : Google Scholar
|
|
4
|
Sandler A, Gray R, Perry MC, et al:
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell
lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sun Y, Ren Y, Fang Z, et al: Lung
adenocarcinoma from East Asian never-smokers is a disease largely
defined by targetable oncogenic mutant kinases. J Clin Oncol.
28:4616–4620. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gaughan EM and Costa DB: Genotype-driven
therapies for non-small cell lung cancer: focus on EGFR, KRAS and
ALK gene abnormalities. Ther Adv Med Oncol. 3:113–125. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Toyooka S, Yatabe Y, Tokumo M, et al:
Mutations of epidermal growth factor receptor and K-ras genes in
adenosquamous carcinoma of the lung. Int J Cancer. 118:1588–1590.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Iwanaga K, Sueoka-Aragane N, Nakamura T,
Mori D and Kimura S: The long-term survival of a patient with
adenosquamous lung carcinoma harboring EGFR-activating mutations
who was treated with gefitinib. Intern Med. 51:2771–2774. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Marchetti A, Martella C, Felicioni L, et
al: EGFR mutations in non-small-cell lung cancer: analysis of a
large series of cases and development of a rapid and sensitive
method for diagnostic screening with potential implications on
pharmacologic treatment. J Clin Oncol. 23:857–865. 2005. View Article : Google Scholar
|
|
10
|
Rekhtman N, Paik PK, Arcila ME, et al:
Clarifying the spectrum of driver oncogene mutations in
biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS
and presence of PIK3CA/AKT1 mutations. Clin Cancer Res.
18:1167–1176. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lindeman NI, Cagle PT, Beasley MB, et al:
Molecular testing guideline for selection of lung cancer patients
for EGFR and ALK tyrosine kinase inhibitors: guideline from the
College of American Pathologists, International Association for the
Study of Lung Cancer, and Association for Molecular Pathology. Arch
Pathol Lab Med. 137:828–860. 2013.
|
|
12
|
Haura EB, Tanvetyanon T, Chiappori A, et
al: Phase I/II study of the Src inhibitor dasatinib in combination
with erlotinib in advanced non-small-cell lung cancer. J Clin
Oncol. 28:1387–1394. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hammerman PS, Sos ML, Ramos AH, et al:
Mutations in the DDR2 kinase gene identify a novel therapeutic
target in squamous cell lung cancer. Cancer Discov. 1:78–89. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Valiathan RR, Marco M, Leitinger B, Kleer
CG and Fridman R: Discoidin domain receptor tyrosine kinases: new
players in cancer progression. Cancer Metastasis Rev. 31:295–321.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ding L, Getz G, Wheeler DA, et al: Somatic
mutations affect key pathways in lung adenocarcinoma. Nature.
455:1069–1075. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Davies H, Hunter C, Smith R, et al:
Somatic mutations of the protein kinase gene family in human lung
cancer. Cancer Res. 65:7591–7595. 2005.PubMed/NCBI
|
|
17
|
An SJ, Chen ZH, Su J, et al:
Identification of enriched driver gene alterations in subgroups of
non-small cell lung cancer patients based on histology and smoking
status. PLoS One. 7:e401092012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lynch TJ, Bell DW, Sordella R, et al:
Activating mutations in the epidermal growth factor receptor
underlying responsiveness of non-small-cell lung cancer to
gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Paez JG, Jänne PA, Lee JC, et al: EGFR
mutations in lung cancer: correlation with clinical response to
gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pao W, Miller V, Zakowski M, et al: EGF
receptor gene mutations are common in lung cancers from ‘never
smokers’ and are associated with sensitivity of tumors to gefitinib
and erlotinib. Proc Natl Acad Sci USA. 101:13306–13311. 2004.
|
|
21
|
Calvo E and Baselga J: Ethnic differences
in response to epidermal growth factor receptor tyrosine kinase
inhibitors. J Clin Oncol. 24:2158–2163. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sasaki H, Shitara M, Yokota K, et al: DDR2
polymorphisms and mRNA expression in lung cancers of Japanese
patients. Oncol Lett. 4:33–37. 2012.PubMed/NCBI
|
|
23
|
Miyamae Y, Shimizu K, Hirato J, et al:
Significance of epidermal growth factor receptor gene mutations in
squamous cell lung carcinoma. Oncol Rep. 25:921–928.
2011.PubMed/NCBI
|
|
24
|
Araki T, Shimizu K, Nakamura T, et al:
Clinical screening assay for EGFR exon 19 mutations using PNA-clamp
smart amplification process version 2 in lung adenocarcinoma. Oncol
Rep. 26:1213–1219. 2011.PubMed/NCBI
|
|
25
|
Araki T, Shimizu K, Nakamura K, et al:
Usefulness of peptide nucleic acid (PNA)-clamp smart amplification
process version 2 (SmartAmp2) for clinical diagnosis of KRAS codon
12 mutations in lung adenocarcinoma: comparison of PNA-clamp
SmartAmp2 and PCR-related methods. J Mol Diagn. 12:118–124. 2010.
View Article : Google Scholar
|
|
26
|
Ali BR, Xu H, Akawi NA, et al: Trafficking
defects and loss of ligand binding are the underlying causes of all
reported DDR2 missense mutations found in SMED-SL patients. Hum Mol
Genet. 19:2239–2250. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Iyoda A, Travis WD, Sarkaria IS, et al:
Expression profiling and identification of potential molecular
targets for therapy in pulmonary large-cell neuroendocrine
carcinoma. Exp Ther Med. 2:1041–1045. 2011.PubMed/NCBI
|
|
28
|
Tanaka K, Hata A, Kida Y, et al: Gefitinib
for a poor performance status patient with squamous cell carcinoma
of the lung harboring EGFR mutation. Intern Med. 51:659–661. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhou C, Wu YL, Chen G, et al: Erlotinib
versus chemotherapy as first-line treatment for patients with
advanced EGFR mutation-positive non-small-cell lung cancer
(OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase
3 study. Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jänne PA, Shaw AT, Pereira JR, et al:
Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell
lung cancer: a randomised, multicentre, placebo-controlled, phase 2
study. Lancet Oncol. 14:38–47. 2013.PubMed/NCBI
|
|
31
|
Sequist LV, von Pawel J, Garmey EG, et al:
Randomized phase II study of erlotinib plus tivantinib versus
erlotinib plus placebo in previously treated non-small-cell lung
cancer. J Clin Oncol. 29:3307–3315. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sakurai H, Asamura H, Watanabe S, Suzuki K
and Tsuchiya R: Clinicopathologic features of peripheral squamous
cell carcinoma of the lung. Ann Thorac Surg. 78:222–227. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Drilon A, Rekhtman N, Ladanyi M and Paik
P: Squamous-cell carcinomas of the lung: emerging biology,
controversies, and the promise of targeted therapy. Lancet Oncol.
13:e418–e426. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Montero JC, Seoane S, Ocaña A and
Pandiella A: Inhibition of SRC family kinases and receptor tyrosine
kinases by dasatinib: possible combinations in solid tumors. Clin
Cancer Res. 17:5546–5552. 2011. View Article : Google Scholar : PubMed/NCBI
|
